BioVie sets up $6.5M at-the-market stock program
What's the deal? BioVie has signed an at-the-market (ATM) equity sales agreement with A.G.P./Alliance Global PartnersDealroom has a profile for this one. Try Dealroom → to sell up to $6.46 million of its Class A common stock. The clinical-stage pharmaceutical company (Nasdaq: BIVI) signed the deal on September 11, 2026, with A.G.P. acting as sales agent.
How it works: Shares may be sold over time as at-the-market offerings under Rule 415, including directly on the Nasdaq Capital Market. BioVie is under no obligation to sell any shares and can suspend or terminate the agreement at any time.
Why now? The offering runs under BioVie's shelf registration on Form S-3, declared effective by the Securities and Exchange Commission on June 29, 2026. A prospectus supplement followed on September 11, 2026.
What's the money for? BioVie said it intends to use net proceeds for general corporate purposes.
What could go wrong? The program gives BioVie equity capital at its discretion, but it also creates the potential for dilution. Because sales trickle into the market over time rather than in a single block, the arrangement could pressure the share price.
The signal: ATM facilities have become a routine funding tool for cash-hungry clinical-stage biotechs, letting them tap public markets in small increments without a formal raise. How actively BioVie draws on the facility will show how much runway it needs.
Read more: minichart.com.sg
Image credit: foteih
